The global Lyme disease treatment market is envisioned to garner $1,636.6 million by 2031, growing from $737.5 million in 2021 at a CAGR of 8.4% from 2022 to 2031.
Chronic Lyme disease is the most frequent kind of tick-borne or vector-borne disease. Lyme disease, also known as Lyme borreliosis, is caused by the bite of a tick infected with the bacteria Borrelia burgdorferi. Early Lyme disease symptoms include circular rashes around the place of the tick bite, fever, nausea, and headache. If Lyme disease is not discovered early, the chronic Lyme disease infection may spread to other organs such as joints and muscles. Many oral treatments for Lyme disease are available in the market, including doxycycline, amoxicillin, and cefuroxime.
Lyme disease is sometimes misunderstood in people as a typical rash or a seasonal allergy because patients with Lyme disease exhibit similar symptoms such as fever and body aching. This aspect is anticipated to stymie the expansion of the Lyme disease treatment market in the approaching years. In addition, a lack of public understanding regarding the prevalence and symptoms of Lyme disease is expected to hamper the market growth.
Antibiotics have been determined to be the most effective therapy for Lyme disease. Patients in the early stages of Lyme disease recover quickly and completely with antibiotics such as doxycycline, amoxicillin, and cefuroxime axetil. Intravenous ceftriaxone may be administered to patients suffering from certain neurological or cardiac illnesses. Patients who have had persistent Lyme disease symptoms for more than 6 months can recover in a few weeks with oral antibiotic therapy.
The coronavirus pandemic has break off all medical and healthcare sectors to the diagnosis and treatment of COVID-19 patients. This has had an influence on various sectors of health and therapy, including the Lyme disease treatment industry. Outpatient visits to healthcare providers have been limited due to a patient's fear about contamination. Indicative patients may be thought to have COVID-19 until negative test results are obtained, implying that examinations for other therapies may be postponed, perhaps leading to poor consequences. Individuals with Lyme disease symptoms were urged to postpone their testing while the coronavirus spread over the world. People were urged to be quarantined since screening for alternative reasons of the patient's symptoms other than COVID-19 was frequently delayed, causing delayed treatments and consequences.
The key players profiled in this report include GSK plc., Pfizer, Inc., Novartis AG, Mayne Pharma Group Limited, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Orion Corporation, Perrigo Company plc., ChartwellPharma, and Almirall, LLC.
Chronic Lyme disease is the most frequent kind of tick-borne or vector-borne disease. Lyme disease, also known as Lyme borreliosis, is caused by the bite of a tick infected with the bacteria Borrelia burgdorferi. Early Lyme disease symptoms include circular rashes around the place of the tick bite, fever, nausea, and headache. If Lyme disease is not discovered early, the chronic Lyme disease infection may spread to other organs such as joints and muscles. Many oral treatments for Lyme disease are available in the market, including doxycycline, amoxicillin, and cefuroxime.
Lyme disease is sometimes misunderstood in people as a typical rash or a seasonal allergy because patients with Lyme disease exhibit similar symptoms such as fever and body aching. This aspect is anticipated to stymie the expansion of the Lyme disease treatment market in the approaching years. In addition, a lack of public understanding regarding the prevalence and symptoms of Lyme disease is expected to hamper the market growth.
Antibiotics have been determined to be the most effective therapy for Lyme disease. Patients in the early stages of Lyme disease recover quickly and completely with antibiotics such as doxycycline, amoxicillin, and cefuroxime axetil. Intravenous ceftriaxone may be administered to patients suffering from certain neurological or cardiac illnesses. Patients who have had persistent Lyme disease symptoms for more than 6 months can recover in a few weeks with oral antibiotic therapy.
The coronavirus pandemic has break off all medical and healthcare sectors to the diagnosis and treatment of COVID-19 patients. This has had an influence on various sectors of health and therapy, including the Lyme disease treatment industry. Outpatient visits to healthcare providers have been limited due to a patient's fear about contamination. Indicative patients may be thought to have COVID-19 until negative test results are obtained, implying that examinations for other therapies may be postponed, perhaps leading to poor consequences. Individuals with Lyme disease symptoms were urged to postpone their testing while the coronavirus spread over the world. People were urged to be quarantined since screening for alternative reasons of the patient's symptoms other than COVID-19 was frequently delayed, causing delayed treatments and consequences.
The key players profiled in this report include GSK plc., Pfizer, Inc., Novartis AG, Mayne Pharma Group Limited, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Orion Corporation, Perrigo Company plc., ChartwellPharma, and Almirall, LLC.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the lyme disease treatment market analysis from 2021 to 2031 to identify the prevailing lyme disease treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the lyme disease treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global lyme disease treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Administration Route
- Oral
- Injectable
- Topical
By Treatment
- Medication
- Tick Removal
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- UAE
- South Africa
- Rest of LAMEA
Key Market Players
- Galaxo SmithKline Plc
- Pfizer, Inc.
- Novartis AG
- Mayne Pharma
- Sun Pharmaceuticals Industries, Inc
- Lupin Pharmaceuticals, Inc.
- Orion Corporation
- Perrigo Company plc
- Chartwell Pharmaceuticals
- Almirall, LLC
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: LYME DISEASE TREATMENT MARKET, BY TREATMENT
CHAPTER 5: LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE
CHAPTER 6: LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: LYME DISEASE TREATMENT MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Lyme Disease Treatment Market," the Lyme disease treatment market was valued at $737.50 million in 2021, and is estimated to reach $1.6 billion by 2031, growing at a CAGR of 8.4% from 2022 to 2031. The rising frequency of Lyme disease in humans and animals necessitates appropriate treatment. The increasing public knowledge of tick-borne infections and veterinary care adds to the expansion of the Lyme disease treatment market.Rising R&D efforts are likely to result in more effective Lyme disease therapy. However, the increasing quantity of generic medications for the treatment is impeding the Lyme disease treatment market growth. Nonetheless, fast advancements in Lyme disease research and diagnostics are expected to lead to the development of novel treatments. Furthermore, increased government efforts in raising awareness regarding animal care and the dangers of Lyme disease are expected to fuel the global Lyme disease treatment market throughout the forecast period.
Lyme disease has drug side effects that restrain market expansion. Some people may experience minor side effects that are readily managed, whilst others who are allergic to a certain prescription may experience severe negative effects. Some of the adverse effects of Lyme disease therapy include swelling of the face, breathing, lips, or throat due to allergic responses, terrible taste in the mouth, nausea, vomiting, vaginal yeast infection, and others. During the first 24 hours of antibiotic medication, some people may experience a greater fever, redder rashes, or more discomfort. This is not an allergic reaction, but rather a consequence of the bacteria dying quickly.
As the number of Lyme disease cases increases throughout the world, healthcare experts and researchers are working hard to produce a vaccine that will protect individuals against infected ticks. For example, a doctor from UMASS Medical School in the U.S. has been working on producing a medicine, pre-exposure prophylaxis, for Lyme disease cure, according to a news article published on Popular Scientific, a global science weekly, on March 2021. The medication has the ability to provide antibodies against Lyme disease in individuals. This Lyme disease medication is now in phase one clinical trials and is scheduled to hit the market in 2023. Additionally, the analysis of oral antibiotics industry and its impact on Lyme disease treatment methods is analyzed in this report. These factors are anticipated to boost the Lyme disease treatment market size in the upcoming years.
The global Lyme disease treatment market share is segmented based on treatment type, administration route, distribution channel, and region. By treatment type, it is classified into medication and tick removal. By administration route, it is classified into oral, injectable, and topical. By distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in the Lyme disease treatment market report include GSK plc., Pfizer, Inc., Novartis AG, Mayne Pharma Group Limited, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Orion Corporation, Perrigo Company plc., ChartwellPharma, and Almirall, LLC.
Impact of COVID-19 on the Global Lyme Disease Treatment Industry
- The COVID-19 pandemic had a negative impact on the growth of treatment methods for the global Lyme disease industry. The pandemic has altered healthcare professionals' attention to preventing viral propagation and treating COVID-19 patients.
- People suffering from Lyme disease are hesitant to visit hospitals due to fear of contracting COVID-19. All of these problems are severely hampering the global lyme disease treatment market trends and expansion.
- The current goal of governments and health ministries of various countries is to adopt immediate actions to reduce the number of persons infected with Lyme disease. While treating this communicable disease is critical, a pandemic might have long-term consequences for persons with noncommunicable disorders.
Key Findings of the Study
- Based on treatment type, the medication sub-segment emerged as the global leader in 2021 and the tick removal sub-segment is anticipated to be the second fastest growing sub-segment during the forecast period
- Based on the administration route, the oral sub-segment emerged as the global leader in 2021 and the injectable sub-segment is predicted to show the fastest growth in the upcoming years
- Based on distribution channel, the hospital pharmacies sub-segment emerged as the global leader in 2021 and the online sub-segment is predicted to show the fastest growth in the upcoming years
- Based on region, the North America market registered the highest market share in 2021 and is projected to maintain the position during the forecast period
Companies Mentioned
- Galaxo Smithkline plc
- Pfizer, Inc.
- Novartis AG
- Mayne Pharma
- Sun Pharmaceuticals Industries, Inc
- Lupin Pharmaceuticals, Inc.
- Orion Corporation
- Perrigo Company plc
- Chartwell Pharmaceuticals
- Almirall, LLC
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
